0101 Search Results


escherichia coli k99  (ATCC)
92
ATCC escherichia coli k99
Representative images of the clearance of E. coli and S. aureus by 5, 10, 12, 15, and 20 UMF MH.
Escherichia Coli K99, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/Escherichia+coli+Serotype%3A+0101%3AK99%2CF41%2CType+GS32+mx%2B1/pmc05343224-99-14-21
Average 92 stars, based on 1 article reviews
escherichia coli k99 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
sl0101  (MedChemExpress)
93
MedChemExpress sl0101
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Sl0101, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/SL+0101-1/pmc12288892-237-19-20
Average 93 stars, based on 1 article reviews
sl0101 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
ap4  (Tocris)
95
Tocris ap4
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Ap4, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/DL-AP4/pmc07925691-243-0-7
Average 95 stars, based on 1 article reviews
ap4 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
anti mouse igmbiot  (SouthernBiotech)
93
SouthernBiotech anti mouse igmbiot
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Anti Mouse Igmbiot, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/Mouse+IgM-BIOT/pmc02043494-237-19-21
Average 93 stars, based on 1 article reviews
anti mouse igmbiot - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
goat anti mouse igm unlb  (SouthernBiotech)
93
SouthernBiotech goat anti mouse igm unlb
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Goat Anti Mouse Igm Unlb, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/Mouse+IgM-UNLB/pmc02700953-120-7-9
Average 93 stars, based on 1 article reviews
goat anti mouse igm unlb - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
sl0101 1  (Tocris)
93
Tocris sl0101 1
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Sl0101 1, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/SL+0101-1/pmc02695780-22-19-28
Average 93 stars, based on 1 article reviews
sl0101 1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
enzymatic kit bio rad ref  (Bio-Rad)
95
Bio-Rad enzymatic kit bio rad ref
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Enzymatic Kit Bio Rad Ref, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/D-10+Hemoglobin+A1C+Reorder+Pack/10__4172_slash_2155___6156__1000610-181-34-38
Average 95 stars, based on 1 article reviews
enzymatic kit bio rad ref - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
ethylpyrimidin 4 yl piperazin 1 yl methyl  (Tocris)
93
Tocris ethylpyrimidin 4 yl piperazin 1 yl methyl
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Ethylpyrimidin 4 Yl Piperazin 1 Yl Methyl, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/SL+0101-1/us12569486-382-18-30
Average 93 stars, based on 1 article reviews
ethylpyrimidin 4 yl piperazin 1 yl methyl - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
lpc  (Larodan)
91
Larodan lpc
( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor <t>SL0101</t> (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).
Lpc, supplied by Larodan, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/LPC/us09212371-535-8-9
Average 91 stars, based on 1 article reviews
lpc - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
d 10 hemoglobin a1c program  (Bio-Rad)
91
Bio-Rad d 10 hemoglobin a1c program
General linear model (GLM) using T2DM status as the dependent variable and gender, age, anthropometrics, glucose, lipids, NLRP3 and ILs as independent variables.
D 10 Hemoglobin A1c Program, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/Amplichek+STI/pmc10216290-98-15-30
Average 91 stars, based on 1 article reviews
d 10 hemoglobin a1c program - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
rsk2 inhibitor sl0101  (Santa Cruz Biotechnology)
86
Santa Cruz Biotechnology rsk2 inhibitor sl0101
General linear model (GLM) using T2DM status as the dependent variable and gender, age, anthropometrics, glucose, lipids, NLRP3 and ILs as independent variables.
Rsk2 Inhibitor Sl0101, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/0101/SL+0101-1/pmc05107120-122-1-7
Average 86 stars, based on 1 article reviews
rsk2 inhibitor sl0101 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Representative images of the clearance of E. coli and S. aureus by 5, 10, 12, 15, and 20 UMF MH.

Journal: BioMed Research International

Article Title: A Comparison of Tissue Engineering Scaffolds Incorporated with Manuka Honey of Varying UMF

doi: 10.1155/2017/4843065

Figure Lengend Snippet: Representative images of the clearance of E. coli and S. aureus by 5, 10, 12, 15, and 20 UMF MH.

Article Snippet: Overnight cultures containing brain heart infusion (BHI) were prepared with fresh isolates of either Escherichia coli K99 ( E. coli ; ATCC: PTA-5951) or Staphylococcus aureus subsp. aureus Rosenbach ( S. aureus ; ATCC: 12600).

Techniques:

Partial and complete clearance radius of (a, c) E. coli and (b, d) S. aureus by various UMF honey bolus. ∗ and ∧ denote clearance that is significantly smaller than 5 and 10 UMF, respectively. # denotes a clearance that is significantly smaller than 12 UMF. $ and @ denote clearance that is significantly smaller than 15 and 20 UMF, respectively ( p < 0.05).

Journal: BioMed Research International

Article Title: A Comparison of Tissue Engineering Scaffolds Incorporated with Manuka Honey of Varying UMF

doi: 10.1155/2017/4843065

Figure Lengend Snippet: Partial and complete clearance radius of (a, c) E. coli and (b, d) S. aureus by various UMF honey bolus. ∗ and ∧ denote clearance that is significantly smaller than 5 and 10 UMF, respectively. # denotes a clearance that is significantly smaller than 12 UMF. $ and @ denote clearance that is significantly smaller than 15 and 20 UMF, respectively ( p < 0.05).

Article Snippet: Overnight cultures containing brain heart infusion (BHI) were prepared with fresh isolates of either Escherichia coli K99 ( E. coli ; ATCC: PTA-5951) or Staphylococcus aureus subsp. aureus Rosenbach ( S. aureus ; ATCC: 12600).

Techniques:

Representative images of the clearance of E. coli and S. aureus by 5 and 20 UMF CG and ES scaffolds. Both 5 and 20 UMF bolus honey as well as sterile discs were used as controls (not pictured).

Journal: BioMed Research International

Article Title: A Comparison of Tissue Engineering Scaffolds Incorporated with Manuka Honey of Varying UMF

doi: 10.1155/2017/4843065

Figure Lengend Snippet: Representative images of the clearance of E. coli and S. aureus by 5 and 20 UMF CG and ES scaffolds. Both 5 and 20 UMF bolus honey as well as sterile discs were used as controls (not pictured).

Article Snippet: Overnight cultures containing brain heart infusion (BHI) were prepared with fresh isolates of either Escherichia coli K99 ( E. coli ; ATCC: PTA-5951) or Staphylococcus aureus subsp. aureus Rosenbach ( S. aureus ; ATCC: 12600).

Techniques: Sterility

Partial clearance radius of (a) E. coli and (b) S. aureus by various MH UMF incorporated into CG and ES scaffolds, as well as UMF honey bolus control. Note that there was no significant difference in clearance by the 5 and 20 UMF when incorporated into CG or ES scaffolds ( p < 0.05).

Journal: BioMed Research International

Article Title: A Comparison of Tissue Engineering Scaffolds Incorporated with Manuka Honey of Varying UMF

doi: 10.1155/2017/4843065

Figure Lengend Snippet: Partial clearance radius of (a) E. coli and (b) S. aureus by various MH UMF incorporated into CG and ES scaffolds, as well as UMF honey bolus control. Note that there was no significant difference in clearance by the 5 and 20 UMF when incorporated into CG or ES scaffolds ( p < 0.05).

Article Snippet: Overnight cultures containing brain heart infusion (BHI) were prepared with fresh isolates of either Escherichia coli K99 ( E. coli ; ATCC: PTA-5951) or Staphylococcus aureus subsp. aureus Rosenbach ( S. aureus ; ATCC: 12600).

Techniques: Control

( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).

Journal: JCI Insight

Article Title: Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression

doi: 10.1172/jci.insight.187684

Figure Lengend Snippet: ( A and B ) Representative images ( A ) and quantification ( B ) of human phospho-kinases in GSC2 cells treated with or without GPNMB recombinant protein (100 ng/mL) for 1 hour. Affected kinases are indicated. ( C and D ) Immunoblots for P-RSK2, RSK2, P-PYK2, and PYK2 in lysates of GSC272 cells treated with GPNMB recombinant protein at the indicated concentrations and time points. ( E ) Extracellular acidification rate (ECAR) of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PYK2 inhibitor PF-271 (15 nM) or RSK1/2 inhibitor SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( F ) Relative L-lactate levels in GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( G ) ECAR of CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 6 independent samples. ( H ) Relative L-lactate levels in CT2A cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM) or SL0101 (100 μM) for 24 hours. n = 3 independent samples. One-way ANOVA test. ( I and J ) Immunoblots for CD133 and SOX2 in lysates of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, I ) or SL0101 (100 μM, J ) for 24 hours. ( K – N ) Tumorsphere formation assays of GSC272 cells treated with GPNMB recombinant protein (100 ng/mL) in the presence or absence of PF-271 (15 nM, K and L) or SL0101 (100 μM, M and N ) for 2 weeks. Scale bar: 200 μm. n = 3–5 independent samples. One-way ANOVA test. ** P < 0.01, *** P < 0.001, n.s., not significant ( P > 0.05).

Article Snippet: Briefly, GSCs were treated with GPNMB recombinant protein in the presence or absence of PF-271 (Selleck Chemicals, S2672) or SL0101 (MedChemExpress, HY-15237) or macrophage/microglia-derived CM.

Techniques: Recombinant, Western Blot

General linear model (GLM) using T2DM status as the dependent variable and gender, age, anthropometrics, glucose, lipids, NLRP3 and ILs as independent variables.

Journal: Biomedicines

Article Title: Differences and Associations of NLRP3 Inflammasome Levels with Interleukins 1α, 1β, 33 and 37 in Adults with Prediabetes and Type 2 Diabetes Mellitus

doi: 10.3390/biomedicines11051315

Figure Lengend Snippet: General linear model (GLM) using T2DM status as the dependent variable and gender, age, anthropometrics, glucose, lipids, NLRP3 and ILs as independent variables.

Article Snippet: HbA1c was analyzed directly using ion exchange high-performance liquid chromatography (HPLC) with commercially available reagents (D-10 Hemoglobin A1c Program #12000949) in a fully automated system (D-10 Hemoglobin Testing System #12010405, Bio-Rad, Hercules, CA, USA).

Techniques: